Bile Acids Activated Receptors Regulate Innate Immunity.
Fiorucci S, Biagioli M, Zampella A, Distrutti E. · 2018
Read Bile Acids Activated Receptors Regulate Innate Immunity. by Fiorucci S, Biagioli M, Zampella A, Distrutti E. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6099188.txt.
Introduction
Fiorucci and co-authors review how bile acid receptors tune innate immunity. Their review appeared in Frontiers in Immunology. Bile acids were once seen as mere fat detergents. They also act as signals made with gut microbes. Two receptors, GPBAR1 and FXR, read those signals.
Both receptors sit on gut and liver immune cells. Macrophages, dendritic cells, and natural killer T cells carry them. Their signals keep these tissues in a tolerant state. That calm stops needless attacks on food and microbes. Receptor drugs show benefit in immune and metabolic disorders. Readers get a route from digestion chemistry to immune control.
Catalog record
| CREATOR | Fiorucci S, Biagioli M, Zampella A, Distrutti E. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 88 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Bile Acids Activated Receptors Regulate Innate Immunity By Stefano Fiorucci, Michele Biagioli, Angela Zampella, Eleonora Distrutti Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2018.01853 ABSTRACT Once known exclusively for their role in nutrients absorption, primary bile acids, chenodeoxycholic and cholic acid, and secondary bile acids, deoxycholic and lithocholic acid, are signaling molecules, generated from cholesterol breakdown by the interaction of the host and intestinal microbiota, acting on several receptors including the G protein-coupled bile acid receptor 1 (GPBAR1 or Takeda G-protein receptor 5) and the Farnesoid-X-Receptor (FXR). Both receptors are placed at the interface of the host immune system with the intestinal microbiota and are highly represented in cells of innate immunity such as intestinal and liver macrophages, dendritic cells and natural killer T cells. Here, we review how GPBAR1 and FXR modulate the intestinal and liver innate immune system and contribute to the maintenance of a tolerogenic phenotype in entero-hepatic tissues, and how regulation of innate immunity might help to explain beneficial effects exerted by GPBAR1 and FXR ligands in immune and metabolic disorders. Regulation of intestinal and liver immune cells reactivity against the enormous variety of antigens continuously delivered to the host by nutrients and intestinal microbiota has been the matter of extensive investigations for many years. At the steady state, the intestinal immune cells, as well as liver-resident macrophages (Kupffer cells), are settled to a state of immune tolerance, i.e., a state of unresponsiveness to tissues and bacterial antigens (1–3). While the mechanisms that support the development of this state of anergy are only partially defined, a growing body of evidence suggests that bile acids contribute to educate intestinal and liver immune cells (4, 5). Bile acids are a peculiar family of steroidal molecules generated by the coordinated cooperation between the host and its intestinal microbiota. Indeed, primary bile acids are generated in the liver from cholesterol side-chain breakdown and then transported through the biliary system, and released into the intestine under nutrients flow. In the intestine, primary bile acids are processed by the microbiota to generate an array of steroidal molecules known as secondary (or degenerated) bile acids [reviewed in Ref. (6)]. All bile acid species are signaling molecules, exerting pleiotropic activities in metabolic and non-metabolic tissues by activating a family of evolutionary conserved receptors collectively known as bile acids activated receptors (BARs) (6). Here, we review how bile acids signal to the host immune system and how this pathway could be exploited for the treatment of intestinal, liver, and systemic disorders. BILE ACID METABOLISM Once known exclusively for their ability to promote the absorption of dietary lipids (i.e., lipids, cholesterol, and fat-soluble vitamins) by the small intestine, bile acids are now recognized to function as regulatory molecules (4–6). Structurally, all mammalian bile acids are steroids and share a C24-5β-cholanoic acid scaffold (Figure 1A). Similarly to other steroidal hormones (i.e., gluco- and mineral-corticoids, estrogens, androgens, etc.), bile acids are generated from cholesterol breakdown. However, in contrast to these “canonical” hormones, bile acids can not be recycled back to cholesterol and, therefore, represent the endproduct of cholesterol metabolism. This pathway account for ~50% of the daily turnover of cholesterol, but only ≈200 mg of cholesterol could be excreted daily with feces as bile acids. In mammalian livers, the conversion of cholesterol in the two primary bile acids, 3α,7α,12α-trihydroxy-5β-cholan-24-oic acid (cholic acid, CA), a tri-hydroxylated bile acid, and 3α,7α-dihydroxy-5β-cholan-24-oic acid (chenodeoxycholic acid, CDCA), a di-hydroxylated bile acid, depends on two metabolic pathways known as the neutral (or classical) and the acidic (or alternative) pathway (5, 6). In the human liver, the neutral pathway accounts for the production of ~90% of primary bile acids and produces almost equal amounts of CA and CDCA. The first, and rate-limiting, enzyme in the neutral pathway is the cholesterol 7α-hydroxylase (CYP7A1) that converts the cholesterol into 7α-hydroxycholesterol (6). This enzymatic reaction is not reversible and cholesterol metabolism can only progress further to primary bile acids. Because of its critical role in bile acid synthesis, the activity of CYP7A1 is tightly regulated by a sophisticated feedback system that senses intracellular bile acids concentrations giving rise to positive and negative intra-hepatic feedback signals (4–6). The main regulatory mechanism in this pathway is contributed by the Farnesoid-X-Receptor (FXR, NR1H4), a nuclear receptor that functions as bile acid sensor in hepatocytes. Once activated by CDCA, its endogenous ligand, FXR represses the transcription of CYP7A1 mRNA by a plurality of mechanisms (Figure 1). Under binding by CDCA, FXR complexes with the Retinoid-X-Receptor (RXR), and the resulting heterodimer binds to specific responsive elements in the promoter of target genes (6). In liver cells, the recruitment of the FXR/RXR heterodimer to the SHP (small heterodimer partner, NR0B2) promoter causes the transcription of this regulatory factor (6). SHP is an atypical nuclear receptor that lacks the DNA binding domain and functions as a corepressor in the regulation of several genes, including CYP7A1 (Figure 1). In addition, activation of intestinal FXR by CDCA in enterocytes causes the release of the fibroblasts growth factor (FGF)-15 (FGF-19 in humans) which circulates back to the liver, binds to the FGF receptor 4 (FGF-R4) on hepatocytes and inhibits CYP7A1 transcription (6). In the classical pathway, the synthesis of CA proceed through a further hydroxylation at C-12 position and the above step is mediated by sterol 12α-hydroxylase (CYP8B1), and without this enzyme only CDCA (i.e., a di-hydroxylated bile acid) is formed (Figure 1). The second pathway, acidic or “alternative” route of bile acid synthesis, generates only CDCA and uses either cholesterol or oxysterols as substrates, depending on their availability in hepatocytes (6). The acidic pathway is initiated by a mitochondrial sterol 27-hydroxylase (CYP27A1) which performs the hydroxylation at C-27 position on cholesterol side chain, followed by hydroxylation on ring B (CYP7B1) and side chain shortening (CYP27A1) and contributes only 10% of CDCA generated in the liver in adulthood. However, activity of CYP27A1 increases significantly in cholestatic disorders such as primary biliary cholangitis (PBC) and might contribute to generation of CDCA. [Figure: (A) Bile acids are synthesized in the liver from cholesterol by two metabolic pathways known as the neutral (or classical) and the acidic (alternative) pathways. In the classical pathway, cholesterol is metabolized to 7α-hydroxycholesterol by cholesterol 7α-hydroxylase (CYP7A1) and then to cholic acid (CA) by sterol 12α-hydroxylase (CYP8A1) or to chenodeoxycholic acid (CDCA) by mitochondrial sterol 27-hydroxylase (CYP27A1). On the other hand, in the acidic pathway, CYP27A1 converts cholesterol into 27-hydroxycholesterol which is then metabolized by 25-hydroxycholesterol 7α-hydroxylase (CYP7B1) into CDCA. The two primary bile acids, CA and CDCA, are then secreted into bile ducts and transported to the intestine where they are respectively converted by microbial bile salt hydrolases, an enzyme expressed predominantly by Bacteroides, Clostridium, Lactobacillus, and Bifidobacteria, and by a bacterial 7α-dehydroxylase, mainly expressed by Clostridium and Eubacterium, in deoxycholic acid (DCA) and in lithocholic acid (LCA) called secondary bile acids. (B) Bile acid metabolism in liver cells and adaptive changes activated in cholestasis by Farnesoid-X-Receptor (FXR). Na+-taurocholate cotransporting polypeptide (NTCP) is a basolateral transporter that allow uptake of bile acids (CA, CDCA, DCA, and LCA) by hepatocytes. Primary and secondary bile acids are then amidated with glycine or taurine by bile acid-CoA:amino acid N-acyltransferase (BAAT) or bile acyl CoA synthetase and then secreted